Business Wire

AGREENA

30.3.2023 08:01:28 CEST | Business Wire | Press release

Share
Farmers’ Fintech Agreena Raises €46M to Scale the Regenerative Revolution

Climate and fintech company Agreena, whose soil carbon platform is one of the largest globally, today announced its Series B raise of €46M. Led by Germany’s leading multi-stage investor HV Capital, the round has an exciting composition of new investors including impact fund AENU and fintech-focused Anthemis. The equity raise is also supported by a doubling-down from existing shareholders, including evergreen food investor Gullspång Re:food, well-established tech investor Kinnevik and Denmark’s Export and Investment fund.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005976/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Agriculture-based carbon removals are considered one of the most readily available and easily scaled solutions for climate change mitigation (Photo: Business Wire)

The sizable raise comes just one year after the company’s €20M Series A. Since then, Agreena has scaled its activities 10X, expanded its geographic footprint to cover farmland in 16 European countries, and partnered with farms to help them transition more than 600,000 hectares towards climate-positive, regenerative farming.

“In order for the world’s farmers to transition to regenerative agriculture and create a scalable climate impact, the financial rails to support and pay them for it need to be built,” said Simon Haldrup, Co-founder and CEO of Agreena. “Agreena is building out technological and financial services infrastructure throughout the agriculture value chain as the industry increasingly becomes a focal point for decarbonisation efforts.”

Momentum around regenerative farming is sweeping the globe, with corporates, governments and supply chains turning their focus to our agricultural soils for carbon removals in order to meet global net-zero targets. Through the adoption of regenerative agriculture practices, farmers will play an increasingly essential role in tackling climate change, food insecurity, and other critical environmental issues. Agreena has developed a way to turn this impact into a new and additional revenue stream for farmers to help finance the transition by leveraging the carbon market.

Via the company’s digital platform, farmers plan, track and validate improvements for their regenerative journey, in the process transitioning from emitting CO2 to drawing CO2 down and storing it within their soils. The improved soil health and biodiversity reduce the need for inputs while enhancing farmers’ resilience to increasingly adverse climate conditions (such as drought or flooding), enhancing the overall operational performance of farms. On the other side of the equation, Agreena’s certificates and downstream services support climate-focused companies already working to decarbonise, as well as companies in the food supply chain increasingly requiring field-level traceability of their agricultural commodities to comply with Scope 3 reporting requirements.

Scaling with Technology

The recent acquisition of remote sensing company Hummingbird Technologies has enabled Agreena to expand its offering beyond farmers to encompass agridata services for supply chain players, governments and other institutions. Prioritising a science-based and technology-first agenda, Agreena’s platform now incorporates a world-leading, AI-based monitoring and verification solution that utilises satellite imagery, coupled with ground-truth data and machine learning to identify and report on-farm regenerative agriculture practices. Offering global monitoring, the company is on a mission to take the lead in supporting the road to net zero for the full value chain.

“Real climate impact is only created at scale and Agreena is perfectly positioned to distribute their carbon farming capabilities across the globe to bring high-quality, verifiable and nature-based carbon credits to the market. Only with carbon removals, can net zero targets be met,” said Alexander Joel-Carbonell, partner at HV Capital.

From Farmer to Fintech

Deeply rooted within the agricultural community, Agreena was originally founded with seed investment from Danish farmers and agricultural families. The company’s next phase introduces a vertically integrated platform and marketplace. Working first with farmers in the field to monitor the carbon impact, the resulting certificates are constructed into scalable portfolios for corporates, tailored to their unique ESG strategy.

The company is taking a lead in providing the technological rails for the growing market with innovative financial solutions. Examples include using sustainable blockchain technology for enhanced traceability and transparency of carbon credits, and e-money and smart contracts to facilitate payment exchanges between climate-conscious corporates and farmers with immediate reconciliation at scale.

“We are on a journey to remove the economic barriers to adoption of regenerative agriculture for farmers and their entire ecosystem - carbon is just the beginning,” concluded Haldrup.

About Agreena

Agreena unlocks the power of soil carbon removals and natural capital to finance the transition to regenerative agriculture. Working in close collaboration with partner farmers across 16 European markets and growing, AgreenaCarbon is the world’s leading soil carbon platform. Combined with market leading satellite monitoring technologies, Agreena’s solutions can support farmers, companies, and governments on the road to net zero.

About Agreena’s Carbon Certification

Agreena’s programme is accredited to the ISO 14064-2 standard, with a third-party verified methodology that is aligned to IPCC science. The company is standards-inclusive and will continue to evolve its offering as policies and science continue to develop. Further, the company is currently undergoing certification with Verra, completion of the process is expected later this year.

About HV Capital

HV Capital is one of the most successful and financially strongest early-stage and growth investors in Europe. Since 2000, HV Capital has invested in around 225 internet and technology companies such as Zalando, Delivery Hero, Flixbus, and HelloFresh through various generations of funds and is continuously looking for the next generation of disruptors from every industry, including FinTech, SaaS, climate tech, and consumer goods. The company supports startups with capital between €500,000 to €50 million and is one of the few venture capital firms in Europe that can finance startups through all growth phases.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005976/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye